News for hackers. Stuff that matters.
Re:Third member of U.S. FDA advisory panel resigns over Alzh... by acdha on Sunday June 13, 2021 @02:57PM (#27495238)
> I take your point that companies can falsely advertise their products. I think there is a place for a government body to make sure claims about healthcare products are factual.

The problem is that deciding whether something is factual is a lot easier for simple things. For something like this, there are vaguer connections between facts like plaque removal and more nebulous things like meaningful outcomes for patients.

> In this particular case we are talking about a drug that appears to not cause any harm.

Other than brain swelling or bleeding, headache, falling, diarrhea, and confusion, delirium or disorientation, you mean?

There are no comments on this comment yet.